We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Stroli – the shopping trolley reimagined for modern needs. The shopping trolley, often associated with a particular image, is an untapped category ready for innovation. The market is flooded with generic, budget-friendly options that lack charm, with the exception of Rolser, which is pricier and claims the green niche. Stroli steps in as the go-to brand, offering a unique approach, positioning, voice, and eco-friendly credentials. Say goodbye to sore hands and plastic bags – Stroli makes shopping a pleasure with its high-quality, stylish trolley bags designed to enhance your convenience and style
days to go: Extended investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Dassie Artisan is a homeware and gift range that is designed in the UK. The company was created after the founders noticed a lack of handmade contemporary products available in the UK market. 
days to go: Expired investment: £108,100
A hardware designer and manufacturer specialising in innovative tools and equipment for yachts. Ark Marine have developed a solution for modern yachts to lift and launch dinghies with ease from a simple pushbutton operated system. According to the team's research, the product market could be potentially valued at over £600m. The company is a member of British Marine and has submitted patents for approval for developments in the future.
days to go: Expired investment: £108,590
TOTM makes organic, eco-friendly & reusable period care products. The company is planning to shake up the £29 billion Femcare industry, with 30k+ online and subscription customers, and listings in Tesco, Superdrug and Urban Outfitters and global B2B clients. Having supplied to large corporates including several global institutions, TOTM is ready for global disruption. To this end, the company is raising funds to accelerate global growth across all channels. The proceeds will also be used to expand its product range, grow awareness, secure more distribution and also invest in tech. 

Pitch Rated

77%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £811,400
Helping SME home builders acquire finance for their projects in the UK. Rubicon Capital has assisted more than 40 project developers in receiving investments for their builds, which has exceeded £75m. In their second year, the company generated £500k in profits and has successfully paid dividends every year since launching in 2015. Two main sources of revenue are upfront fees for connecting borrowers with lenders and administration fees in the form of long-term consultancy and performance assistance. Money raised from this crowdfunding round will be used to expand the Rubicon Capital team and grow their business to attract more home builders requiring financial assistance, in addition to increasing the number of sources offering finance.
days to go: Expired investment: £128,510
Rockit design innovative sleep products that centre on child sleep issues. The company has launched an award winning portable baby rocker and since the launch in October 2017 over 14,000 Rockits have been sold. The product will be in John Lewis stores in spring and also in JoJo Maman Bebe in the summer. The funding will allow them to increase their marketing in the UK and overseas. It will also to produce the tooling for the first follow up product.
days to go: Expired investment: £253,120
Blake LDN is a British woman's fashion brand that solely focuses on knitwear. Blake LDN's aim is to create contemporary knitwear only using the highest quality yarn suppliers and the most skilled craftsman but for an affordable price. 
days to go: Expired investment: £8,880
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph